颖泰生物
(920819)
| 流通市值：51.20亿 | | | 总市值：51.97亿 |
| 流通股本：12.08亿 | | | 总股本：12.26亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,434,358,148.32 | 2,966,387,661.78 | 1,387,275,846.94 | 5,829,882,357.93 |
| 营业收入 | 4,434,358,148.32 | 2,966,387,661.78 | 1,387,275,846.94 | 5,829,882,357.93 |
| 二、营业总成本 | 4,449,365,908.78 | 2,972,244,005.69 | 1,390,914,399.31 | 5,982,883,377.41 |
| 营业成本 | 3,885,232,288.87 | 2,606,516,151.69 | 1,202,835,902.89 | 5,221,224,027.45 |
| 税金及附加 | 26,134,401.61 | 15,971,918.65 | 9,556,162.48 | 31,594,916.23 |
| 销售费用 | 66,451,537.7 | 44,813,768.83 | 20,156,761.92 | 95,811,650.5 |
| 管理费用 | 236,624,105.8 | 156,054,675.12 | 88,033,029.83 | 328,210,910.5 |
| 研发费用 | 118,079,806.27 | 78,896,388.6 | 39,977,073.76 | 173,428,698.2 |
| 财务费用 | 116,843,768.53 | 69,991,102.8 | 30,355,468.43 | 132,613,174.53 |
| 其中:利息费用 | 121,582,410.54 | 81,531,049.94 | 36,902,221.67 | 185,363,434.92 |
| 其中:利息收入 | 12,584,320.13 | 8,660,485.32 | 4,215,698.17 | 23,687,661.52 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 725,584.92 | 1,178,100.54 | 977,768.91 | - |
| 加:投资收益 | -16,194,477.36 | 20,751,086.12 | 4,521,605.02 | -226,970,520.98 |
| 资产处置收益 | 16,550,638.59 | 11,784,053.1 | 2,978,650.61 | 3,207,056.93 |
| 资产减值损失(新) | -3,446,963.22 | -5,388,207.16 | 284,252.24 | -276,155,710.13 |
| 信用减值损失(新) | 2,296,345.97 | 571,265.78 | 401,294.25 | -3,728,302.1 |
| 其他收益 | 25,213,280.8 | 14,514,805.93 | 6,257,836.88 | 27,694,384.24 |
| 四、营业利润 | 10,136,649.24 | 37,554,760.4 | 11,782,855.54 | -628,954,111.52 |
| 加:营业外收入 | 3,124,727.02 | 1,042,631.02 | 219,958.77 | 5,950,140.66 |
| 减:营业外支出 | 5,204,182.65 | 3,674,252.56 | 794,553.84 | 15,498,385.57 |
| 五、利润总额 | 8,057,193.61 | 34,923,138.86 | 11,208,260.47 | -638,502,356.43 |
| 减:所得税费用 | 19,688,515.2 | 21,961,019.09 | 10,526,710.07 | -42,522,270.55 |
| 六、净利润 | -11,631,321.59 | 12,962,119.77 | 681,550.4 | -595,980,085.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -11,631,321.59 | 12,962,119.77 | 681,550.4 | -595,980,085.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -9,626,574.46 | 15,290,875.02 | 2,348,404.41 | -587,333,739.05 |
| 少数股东损益 | -2,004,747.13 | -2,328,755.25 | -1,666,854.01 | -8,646,346.83 |
| 扣除非经常损益后的净利润 | -38,211,048.87 | 992,860.09 | -2,420,366.69 | -595,258,848.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | 0.01 | 0 | -0.48 |
| (二)稀释每股收益 | -0.01 | 0.01 | 0 | -0.48 |
| 八、其他综合收益 | 24,928,584.13 | 35,291,850.54 | 11,680,166.76 | -35,228,547.61 |
| 归属于母公司股东的其他综合收益 | 24,928,584.13 | 35,291,850.54 | 11,680,166.76 | -35,228,547.61 |
| 九、综合收益总额 | 13,297,262.54 | 48,253,970.31 | 12,361,717.16 | -631,208,633.49 |
| 归属于母公司股东的综合收益总额 | 15,302,009.67 | 50,582,725.56 | 14,028,571.17 | -622,562,286.66 |
| 归属于少数股东的综合收益总额 | -2,004,747.13 | -2,328,755.25 | -1,666,854.01 | -8,646,346.83 |
| 公告日期 | 2025-10-24 | 2025-08-15 | 2025-04-18 | 2025-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |